Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22874791 | 0.98 | DPP4 (0.47) | DPP4NAMPTCNR2HSD11B1TPSAB1 | |
| SCHEMBL22874789 | 0.97 | TPSAB1 (0.46) | DPP4NAMPTCNR2HSD11B1TPSAB1 | |
| SCHEMBL17540498 | 0.93 | NAMPT (0.51) | DPP4NAMPTCNR2TPSAB1TPSD1 | |
| SCHEMBL26228688 | 0.88 | HSD11B1 (0.48) | DPP4NAMPTCNR2HSD11B1TPSAB1 | |
| SCHEMBL22874986 | 0.87 | GNAI3 (0.48) | DPP4NAMPTTPSAB1TPSD1TPSG1 | |
| SCHEMBL22875317 | 0.87 | HSD11B1 (0.50) | DPP4NAMPTHSD11B1TPSAB1TPSD1 | |
| SCHEMBL25444736 | 0.85 | NAMPT (0.42) | DPP4NAMPTCNR2TPSAB1TPSD1 | |
| SCHEMBL17540513 | 0.85 | NAMPT (0.42) | DPP4NAMPTTPSAB1TPSD1TPSG1 | |
| SCHEMBL25443838 | 0.85 | NAMPT (0.42) | DPP4NAMPTTPSAB1TPSD1TPSG1 | |
| SCHEMBL22875319 | 0.85 | HSD11B1 (0.44) | DPP4NAMPTHSD11B1TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | DPP4 4610/4885NAMPT 4690/4885CNR2 4757/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | DPP4 4109/4885NAMPT 4578/4885CNR2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.